GAP Supply Act
Summary
The GAP Supply Act (HR7528) is an early-stage procedural bill with no funding authorization. It extends a regulatory timeline for compounding facilities during drug shortages but has near-zero near-term market impact. Current real market data shows $VTRS at $15.04 within its 52-week range of $8.19–$16.47, with a +11.32% 30-day gain reflecting broader market trends, not this bill.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7528 is an early-stage procedural bill with zero funding — no direct market impact.
- 2.Primary effect is regulatory relief for compounding pharmacies (mostly private companies), not public company earnings.
- 3.$VTRS's 11.32% 30-day gain to $15.04 is unrelated to this bill; driven by broader market dynamics.
- 4.No actionable trade signal. Monitor committee markup for any amendments that add funding or expand scope.
Market Implications
No actionable market implications from HR7528 in its current state. at $15.04 within range $8.19–$16.47 shows no bill-specific catalyst. Investors should ignore this bill unless it receives a committee markup date, which would signal minimal advancement. For generic injectable exposure, $VTRS's recent 30-day trend (+11.32%) suggests broader momentum that may continue independent of legislative noise.
Full Analysis
- What happened and status: HR7528 was introduced by Rep. Carter (R-GA) on February 12, 2026, and referred to the House Energy and Commerce Committee. It has not moved beyond this single referral. The bill amends Section 503B of the FD&C Act to change a timing requirement for outsourcing facilities — giving them 180 calendar days (instead of 'at the time') to continue supplying a drug after it is placed on the FDA shortage list. This is a purely procedural regulatory change. No funds are authorized or appropriated. 2) The money trail: $0. This bill contains no spending authorization, no tax credits, no grants, and no procurement directives. It modifies FDA regulatory compliance timelines only. The mechanism is a reduction in legal risk for compounding pharmacies, not a market-enlarging subsidy. 3) Structural winners and losers: The primary beneficiaries are small-to-mid-sized 503B outsourcing facilities (mostly private companies, not publicly traded). Viatris and other generic injectable manufacturers face marginally increased competition from more authorized compounding during shortages, but the effect is too small and indirect to materially alter earnings. No public pure-play compounding pharmacy tickers exist on US exchanges. 4) Real market data context: is trading at $15.04, up +3.08% over 7 days and +11.32% over 30 days. The stock is near the top of its 52-week range ($8.19–$16.47), but this move is attributable to broader sector rotation and company-specific factors (e.g., patent settlements, generic drug pricing cycles), not this bill. 5) Timeline: The bill is at the earliest possible stage. To become law, it must pass committee markup, pass the House floor, pass the Senate (no companion bill exists), and be signed by the President. Given the 119th Congress is in its second session (2026 is an election year), the window for advancing non-urgent regulatory bills is narrow. Passage probability is low.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →